Article detail · 2023
Celecoxib Derivatives Containing Pyrazole Linked-Sulfonamide Moiety: Carbonic Anhydrase I–II and Acetylcholinesterase Inhibition Profiles, Molecular Docking Studies
- Year
- 2023
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue ChemistrySelect
- Catalog match (ISSN) ChemistrySelect
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
OpenAlex · English
Abstract Heterocyclic pyrazole compounds have cytotoxic, anticancer, antimicrobial, anti‐inflammatory properties, as well as their derivatives containing sulfonamide moiety, show superior effects on inhibiting various enzymes. Pre‐synthesized celecoxib‐derived compounds were studied for their inhibitory effects on human carbonic anhydrase (hCA I and hCA II) isoforms and acetylcholinesterase (AChE). The compound containing 2,3 dimethoxyphenyl functional groups from the celecoxib derivative containing this sulfonamide moiety showed a strong inhibitory effect with K i values at 21.70±2.50 nM, 4.70±2.20 nM, and 4.58±0.80 nM for hCA I, hCA II, and AChE, respectively. In addition, these compounds were evaluated against acetazolamide (AZA) and tacrine (TAC), which are used as standard inhibitors for the studied enzymes. The compound obtained as a result of the reaction of pyrazole compounds with propionic anhydride and showing the best inhibition effect had higher inhibitory activity than the standard inhibitors we used. In addition, molecular docking analyses to the strongest inhibitor were performed to identify possible binding mechanisms with the active sites of all three enzymes. Based on both in vitro and molecular docking analysis results, this compound was determined as a potential inhibitor of AChE, hCA I, and hCA II isoenzymes.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
17 citations
OpenAlex cited_by_count (cache / database)
26 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- Lactoperoxidase Inhibition of Celecoxib Derivatives Containing the Pyrazole Linked-Sulfonamide Moiety: Antioxidant Capacity, Antimicrobial Activity, and Molecular Docking Studies 2024
- Lactoperoxidase Inhibition of Celecoxib Derivatives Containing the Pyrazole Linked‐Sulfonamide Moiety: Antioxidant Capacity, Antimicrobial Activity, and Molecular Docking Studies 2024
- Lactoperoxidase Inhibition of Celecoxib Derivatives Containing the Pyrazole Linked‐Sulfonamide Moiety: Antioxidant Capacity, Antimicrobial Activity, and Molecular Docking Studies 2024
- In vitro bioactivities and in silico enzyme interactions of abietatrien-3β-ol by bio-guided isolation from Nepeta italica subsp. italica 2025
- In vitro bioactivities and in silico enzyme interactions of abietatrien-3β-ol by bio-guided isolation from Nepeta italica subsp. italica 2025
- In vitro bioactivities and in silico enzyme interactions of abietatrien-3 β-ol by bio-guided isolation from Nepeta italica subsp. italica 2024
- Synthesis of Novel Isoindolinones: Carbonic Anhydrase Inhibition Profiles, Antioxidant Potential, Antimicrobial Effect, Cytotoxicity and Anticancer Activity 2025
- Synthesis of Novel Isoindolinones: Carbonic Anhydrase Inhibition Profiles, Antioxidant Potential, Antimicrobial Effect, Cytotoxicity and Anticancer Activity 2025
- Synthesis of Novel Isoindolinones: Carbonic Anhydrase Inhibition Profiles, Antioxidant Potential, Antimicrobial Effect, Cytotoxicity and Anticancer Activity 2025
- In Vitro Evaluation of Flavonoids for Enzyme Inhibition, Antioxidant, Antimicrobial and Anticancer Properties with Molecular Docking Insights 2025